ID   MM253c1-3D
AC   CVCL_UM70
DR   cancercelllines; CVCL_UM70
DR   Wikidata; Q95990209
RX   PubMed=6534346;
RX   PubMed=6690060;
RX   PubMed=7060019;
CC   Selected for resistance to: ChEBI; CHEBI_4305; Dacarbazine (DTIC; (5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide)).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_UM66 ! MM253c1
SX   Male
AG   46Y
CA   Cancer cell line
DT   Created: 25-02-19; Last updated: 19-12-24; Version: 8
//
RX   PubMed=6534346; DOI=10.1038/icb.1984.57;
RA   Hayward I.P., Parsons P.G.;
RT   "Epigenetic effects of the methylating agent 5-(3-methyl-1-triazeno)
RT   imidazole-4-carboxamide in human melanoma cells.";
RL   Aust. J. Exp. Biol. Med. Sci. 62:597-606(1984).
//
RX   PubMed=6690060;
RA   Hayward I.P., Parsons P.G.;
RT   "Comparison of virus reactivation, DNA base damage, and cell cycle
RT   effects in autologous human melanoma cells resistant to methylating
RT   agents.";
RL   Cancer Res. 44:55-58(1984).
//
RX   PubMed=7060019;
RA   Parsons P.G., Smellie S.G., Morrison L.E., Hayward I.P.;
RT   "Properties of human melanoma cells resistant to
RT   5-(3',3'-dimethyl-1-triazeno)imidazole-4-carboxamide and other
RT   methylating agents.";
RL   Cancer Res. 42:1454-1461(1982).
//